Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses

Sankhwar, Monica; Sankhwar, Satya Narayan; Gupta, Gopal; Rajender, Singh

doi:10.1038/srep27018

Cited by 22 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis is prone to systematic errors (bias) or random errors (play of chance) due to dispersed data and repeated significance testing [ 100 ]. To obtain more comprehensive assessment, trial sequential analysis (TSA) (version 0.9; Copenhagen Trial Unit, Copenhagen, Denmark, 2011) was used to calculate required information size (number of samples) and to confirm statistical reliability of meta-analysis.…”

Section: Methodsmentioning

confidence: 99%

Association between 8q24 rs6983267 polymorphism and cancer susceptibility: a meta-analysis involving 170,737 subjects

et al. 2017

View full text Add to dashboard Cite

Published data on the association between 8q24 rs6983267 polymorphism and cancer risk are inconsistent. Thus, we conducted a meta-analysis to evaluate the relationship between rs6983267 polymorphism and cancer risk. We searched on PubMed, EMBASE, Web of Science and China National Knowledge Infrastructure (CNKI) up to November 1, 2016 for relevant studies. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the strength of this association. We included 78 case-control studies with a total of 73,996 cases and 96,741 controls in this meta-analysis. The pooled results showed that rs6983267 polymorphism was significantly associated with increased risk of overall cancer in all genetic models (dominant model: OR = 1.19, 95% CI = 1.13–1.26; recessive model: OR = 1.19, 95% CI = 1.14–1.25; homozygous model: OR= 1.31, 95% CI = 1.23–1.40; heterozygous model: OR = 1.14, 95% CI = 1.10–1.19; allelic model: OR = 1.14, 95% CI = 1.11–1.18). Stratified analyses indicated that rs6983267 significantly increased the risk of colorectal cancer in Caucasians, prostate cancer in Caucasians and Asians, thyroid cancer in Caucasians and lung cancer in Asians. When studies were stratified by study quality, source of controls and genotyping method, significant associations were especially found in the high quality studies, the publication-based studies, the hospital-based studies, and the PCR-RFLP studies. Additional well-designed studies with large samples should be performed to validate our results.

show abstract

Section: Methodsmentioning

confidence: 99%

Association between 8q24 rs6983267 polymorphism and cancer susceptibility: a meta-analysis involving 170,737 subjects

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Interestingly, those meta-analyses results showed that the XPC Ala499Val polymorphism was not associated with increased risk of most tumors including breast, colorectal, gastric, and lung. However, their results demonstrated that the XPC Ala499Val polymorphism may contribute to susceptibility to bladder cancer, especially among Caucasians (33,34). Moreover, our pooled results showed that this polymorphism is significantly associated with risk of CMM.…”

Section: Subgroupmentioning

confidence: 56%

Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis

Asadian

Niktabar

Ghelmani

et al. 2020

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

Background: A number of studies have reported that the xeroderma pigmentosum complementation group C (XPC) polymorphisms are associated with cutaneous malignant melanoma (CMM) susceptibility. But the results of those studies were inconsistent. Here, we performed a study to obtain a more conclusive result on the association of XPC polymorphisms with risk of CMM. Methods: The XPC Lys939Gln and Ala499Val polymorphisms were genotyped in 150 CMM cases and 150 controls by PCR-RFLP assay. Subsequently, all published relevant studies were identified through a comprehensive literature search in PubMed, Web of Science, and CNKI databases. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of correlation. Results: There was no significant association between XPC Lys939Gln and Ala499Val polymorphisms and CMM risk in our population. A total of 15 case-control studies including ten studies with 5,990 cases and 7,697 controls on XPC Lys939Gln and five studies with 3,139 cases and 3,721 controls on XPC Ala499Val polymorphism were selected. Pooled data revealed that XPC Lys939Gln (C vs. A: OR = 1.108, 95% CI 1.008– 1.217; P = 0.033) and Ala499Val (C vs. A: OR = 0.918, 95% CI 0.850–0.992; p = 0.031; CC+CA vs. AA: OR = 0.904, 95% CI 0.819–0.997; p = 0.043) polymorphisms were significantly associated with an increased risk of CMM. Moreover, stratified analyses by ethnicity revealed that the XPC Ala499Val and Lys939Gln polymorphisms were significantly associated with risk of CMM in Caucasians and mixed populations, respectively. Conclusions: This meta-analysis result suggested that XPC Lys939Gln and Ala499Val polymorphisms were significantly associated with risk of CMM.

show abstract

“…The SNP was also found to be significantly associated with an elevated overall cancer risk in a meta‐analysis (He et al., ). However, two other meta‐analyses have reported a lack of association (Francisco et al., ; Sankhwar et al., ). Therefore, further work in combination with functional characterization of this SNP is needed.…”

Section: Discussionmentioning

confidence: 99%

A 3′ untranslated region polymorphism rs2304277 in the DNA repair pathway gene OGG1 is a novel risk modulator for urothelial bladder carcinoma

Ahmed

Nawaz

Noreen

et al. 2017

Annals of Human Genetics

View full text Add to dashboard Cite

Altered DNA repair capacity may affect an individual's susceptibility to cancers due to compromised genomic integrity. This study was designed to elucidate the association of selected polymorphisms in DNA repair genes with urothelial bladder carcinoma (UBC). OGG1 rs1052133 and rs2304277, XRCC1 rs1799782 and rs25487, XRCC3 rs861539, XPC rs2228001, and XPD rs13181 were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 200 UBC cases and 200 controls. We found association of OGG1 rs2304277 [odds ratio (OR) = 3.55, 95% confidence interval (CI) = 1.79-7.06] and XPC rs2228001 (OR = 2.38, 95% CI = 1.43-3.94) with UBC. In stratified analysis with respect to smoking status, OGG1 rs2304277 and XPC rs2228001 exhibited increased risk in smokers [(rs2304277 OR = 4.96, 95% CI = 1.51-16.30) (rs2228001 OR = 2.19, 95% CI = 1.02-4.72)] as well as nonsmokers [(rs2304277 OR = 2.95, 95% CI = 1.26-6.90) (rs2228001 OR = 2.57, 95% CI = 1.31-5.04)]. These polymorphisms were also associated with both low-grade [(rs2304277 OR = 3.73, 95% CI = 1.72-8.09) (rs2228001 OR = 2.18, 95% CI = 1.21-3.92)] and high-grade tumors [(rs2304277 OR = 3.45, 95% CI = 1.52-7.80) (rs2228001 OR = 2.81, 95% CI = 1.48-5.33)] as well as with non-muscle-invasive bladder cancer [(rs2304277 OR = 4.03, 95% CI = 1.87-8.67) (rs2228001 OR = 2.14, 95% CI = 1.20-3.81)] and muscle-invasive bladder cancer [(rs2304277 OR = 3.06, 95%CI = 1.31-7.13) (rs2228001 OR = 2.95, 95%CI = 1.51-5.75)]. This is the first study on DNA repair gene polymorphisms and UBC in the Pakistani population. It identifies OGG1 rs2304277 and replicates XPC rs2228001 as significant modulators of UBC susceptibility.

show abstract

Polymorphisms in the XPC gene affect urinary bladder cancer risk: a case-control study, meta-analyses and trial sequential analyses

Cited by 22 publications

References 27 publications

Association between 8q24 rs6983267 polymorphism and cancer susceptibility: a meta-analysis involving 170,737 subjects

Association between 8q24 rs6983267 polymorphism and cancer susceptibility: a meta-analysis involving 170,737 subjects

Association of XPC Polymorphisms with Cutaneous Malignant Melanoma Risk: Evidence from a Meta-Analysis

A 3′ untranslated region polymorphism rs2304277 in the DNA repair pathway gene OGG1 is a novel risk modulator for urothelial bladder carcinoma

Contact Info

Product

Resources

About